Enterprise Value

126.9B

Cash

12.28B

Avg Qtr Burn

N/A

Short % of Float

1.74%

Insider Ownership

0.10%

Institutional Own.

78.90%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KRAZATI (Adagrasib) (MRTX849) KRAS G12C Inhibitor Details
Cancer, Lung cancer, Colorectal cancer , Solid tumor/s, Non-small cell lung carcinoma

Approved

Quarterly sales

Approved

Quarterly sales

Eliquis Details
Stroke, Atrial fibrillation, Blood clots

Approved

Quarterly sales

Breyanzi® (lisocabtagene maraleucel) Details
Chronic lymphocytic leukemia, Blood cancer, Small lymphocytic lymphoma

Approved

Quarterly sales

Sotyktu (deucravacitinib) Details
Psoriasis, Skin disease/disorder

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Reblozyl®(luspatercept-aamt) Details
Cancer, Anemia, Blood cancer, Mutant Myelodysplastic Syndromes

Approved

Quarterly sales

Zeposia (ozanimod) Details
Multiple sclerosis, Ulcerative colitis

Approved

Quarterly sales

Camzyos®(mavacamten) Details
Hypertrophic cardiomyopathies

Approved

Quarterly sales

Augtyro™ (Repotrectinib) Details
Cancer, Non-small cell lung carcinoma, Solid tumor/s

Approved

Quarterly sales

Opdivo® (nivolumab) + chemotherapy Details
Cancer, Non-small cell lung carcinoma

PDUFA

Approval decision

KarXT (xanomeline-trospium) Details
Mental health, Schizophrenia

PDUFA

Approval decision

KRAZATI (Adagrasib) + Cetuximab Details
Cancer, Colorectal cancer , Solid tumor/s

PDUFA

Approval decision

PDUFA

Approval decision

Breyanzi® (lisocabtagene maraleucel) Details
B-cell lymphoma, Non-Hodgkin lymphoma, Mantle cell lymphoma

PDUFA

Approval decision

Breyanzi® (lisocabtagene maraleucel) Details
B-cell lymphoma, Non-Hodgkin lymphoma, Follicular lymphoma

PDUFA

Approval decision

Milvexian Details
Acute coronary syndrome, Stroke, Atrial fibrillation

Phase 3

Data readout

BMS-986278 [(LPA1) antagonist] Details
Lung disease, Idiopathic pulmonary fibrosis

Phase 3

Data readout

KRAZATI (Adagrasib) (MRTX849) Details
Solid tumor/s, Lung cancer, Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

KarXT (M1/M4 muscarinic agonist) Details
Schizophrenia, Mental health, Alzheimer's disease

Phase 3

Data readout

KarXT (M1/M4 muscarinic agonist) Details
Mental health, Schizophrenia

Phase 3

Data readout

Phase 3

Update

Adagrasib (MRTX849) + cetuximab Details
Solid tumor/s, Colorectal cancer , Cancer

Phase 3

Update

Phase 3

Update

Phase 3

Update

Phase 3

Update

Phase 3

Update

Opdivo® (nivolumab) + Yervoy (ipilimumab) Details
Non-small cell lung carcinoma, Cancer

Phase 3

Update

Phase 3

Update

Adagrasib (MRTX849) + Pembrolizumab Details
Cancer, Lung cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 3

Update

A/I CELMoD (CC-99282) Details
Relapsed/ refractory lymphoma, Non-Hodgkin lymphoma, Cancer

Phase 2

Interim update

Phase 2

Initiation

Phase 1/2

Data readout

Phase 1/2

Data readout

MRTX1133 Details
Cancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Lung cancer

Phase 1/2

Data readout

Golcadomide (CELMoD™ Agent) +rituximab Details
Blood cancer, Diffuse large B cell lymphoma, Non-Hodgkin lymphoma

Phase 1/2

Update

Adagrasib (MRTX849) KRAS G12C Inhibitor + VS-6766 in KRASG12C-mutant Details
Cancer, Solid tumor/s, Non-small cell lung carcinoma, Lung cancer

Phase 1/2

Initiation

Golcadomide (CELMoD™ Agent) Details
Non-Hodgkin lymphoma, Blood cancer

Phase 1b

Update

KarXT (M1/M4 muscarinic agonist) Details
Schizophrenia, Mental health

Phase 1b

Update

KAR-2618 Details
Mental health, Major depressive disorder

Phase 1b

Initiation

BMS-986393/CC-95266 Details
High Refractory Multiple Myeloma

Phase 1

Update

BMS-986365 (CC-94676) Details
Castration-resistant prostate cancer

Phase 1

Update